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Research Highlights: 
- Gene expression data from one animal experiment and two human intervention 
studies were quantitatively compared 
- A multivariate model was used to estimate effect sizes of gene expression in PBMCs 
and WAT of both species 
- Intertissue correlations between PBMCs and WAT were significant for estrogen-
related genes in both humans and rats 
- Interspecies correlations were significant for oxidative phosphorylation in PBMCs 
and estrogen-related genes in WAT 
- Estimation of gene expression effect size and correlations between tissues and species 
can be useful for risk assessment 
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Abstract 
Quantitative insight into species differences in risk assessment is expected to reduce 
uncertainty and variability related to extrapolation from animals to humans. This paper 
explores quantification and comparison of gene expression data between tissues and species 
from intervention studies with isoflavones. 
Gene expression data from peripheral blood mononuclear cells (PBMCs) and white adipose 
tissue (WAT) after 8wk isoflavone interventions in postmenopausal women and 
ovariectomized F344 rats were used. A multivariate model was applied to quantify gene 
expression effects, which showed 3 to 5-fold larger effect sizes in rats compared to humans. 
For estrogen responsive genes, a 5-fold greater effect size was found in rats than in humans. 
For these genes, intertissue correlations (r=0.23 in humans, r=0.22 in rats) and interspecies 
correlation in WAT (r=0.31) were statistically significant. Effect sizes, intertissue and 
interspecies correlations for some groups of genes within energy metabolism, inflammation 
and cell cycle processes were significant, but weak. 
Quantification of gene expression data reveals differences between rats and women in effect 
magnitude after isoflavone supplementation. For risk assessment, quantification of gene 
expression data and subsequent calculation of intertissue and interspecies correlations within 
biological pathways will further strengthen knowledge on comparability between tissues and 
species. 
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1. Introduction 
Isoflavones are phytoestrogens present in soy (products) and the main isoflavones are daidzein, 
genistein and glycitein. Epidemiological studies in Asian countries suggest that isoflavones are 
beneficial for health, because soy consumption was associated with lower incidence of several 
types of cancer, osteoporosis and cardiovascular disease (Messina, 2010). However, results 
from in vitro and animal studies still raise doubts about their safety (Andres et al., 2011; 
Assessment, 2007; Wuttke et al., 2007), especially because of the putative activation of 
estrogen receptors (ER). Recently, we showed that the ER might not be the main transcription 
factor responsible for the induced gene expression effects of isoflavones in human peripheral 
blood mononuclear cells (PBMCs) and adipose tissue (van der Velpen et al., 2013; van der 
Velpen et al., 2014). Also, it has been shown that the proportions of the more active free 
isoflavones in the circulation were markedly higher (20-150 times) in rodents than in humans 
(Setchell et al., 2011). Furthermore, over the past few years human studies have not confirmed 
the adverse effects found in in vitro and in animal studies, except for a disputable adverse effect 
related to endometrial thickness (Unfer et al., 2004), which was not confirmed in more recent 
studies (Alekel et al., 2014; D'Anna et al., 2007; Palacios et al., 2007; Palacios et al., 2010). 
Altogether, this further raises the question of the applicability of animal models to predict 
effects of isoflavones in humans. 
In risk assessment, potential adverse health effects in humans are generally extrapolated from 
animal experiments, which causes one of several sources of variability and uncertainty in risk 
assessment (Abt et al., 2010). Application of new techniques, like quantitative structure-
activity relationship modelling, physiologically based biokinetic modelling and 
transcriptomics, might enable better quantification of interspecies differences (Pettit et al., 
2010). Especially the use of transcriptomics is promising, as this data can be derived in a similar 
manner from animal experiments and human studies, enabling direct comparison. Furthermore, 
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transcriptomics can be considered a powerful tool for detection of early effect markers, 
especially when changes in gene expression are considered within biological pathways (Elliott 
et al., 2007) with e.g. gene set enrichment analysis (GSEA (Subramanian et al., 2005)). Several 
studies have demonstrated the use of gene expression in the risk assessment of e.g. dibutyl 
phtalate (Euling et al., 2013a; Euling et al., 2013b; Makris et al., 2013), coumarin (Kienhuis et 
al., 2009a), acetaminophen (Kienhuis et al., 2009c) and benzo(a)pyrene (Moffat et al., 2015). 
These often regard qualitative and semi-quantitative approaches (Bourdon-Lacombe et al., 
2015), while quantitative approaches could enable better comparison between tissues and 
species and advance the use of gene expression in risk assessment (Burgess-Herbert & Euling, 
2013; Chepelev et al., 2015) .  
In this paper, we aim to quantitatively evaluate and compare gene expression data from two 
tissues (PBMCs and white adipose tissue (WAT)) after isoflavone interventions in women and 
rats using a multivariate model.  
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2. Materials and Methods 
Data from two human intervention studies and one rat experiment were used, aligned for dose, 
duration and target group, and obtained with standardized gene expression methods. 
2.1 Human intervention studies 
The two human studies, ISO and ISO II, were conducted at the Division of Human Nutrition 
of Wageningen University, approved by the Medical Ethical Committee of this university and 
described earlier by Van der Velpen et al. (van der Velpen et al., 2013; van der Velpen et al., 
2014). Both studies, were double-blind placebo-controlled crossover studies with eight week 
intervention periods and eight week washout periods in between.  
The ISO study determined the effects on PBMC gene expression of an isoflavone supplement 
in 27 equol-producing postmenopausal women. In the ISO II study, the effects of the same 
supplement on WAT gene expression were determined in 24 postmenopausal women, both 
equol producers (n=7) and non-producers (n=17). In- and exclusion criteria for both studies 
and the screening procedure for equol producers have previously been described (van der 
Velpen et al., 2013; van der Velpen et al., 2014). In brief, exclusion criteria were use of soy 
products or isoflavone supplements, hormone related medication, anti-inflammatory 
medicines, or antibiotics in the past 3 months. In addition, women with severe heart conditions, 
thyroid conditions, removed ovaries or prior diagnosis of cancer were excluded, as well as 
known alcohol and drug abuse, smoking habits, a BMI above 35 kg/m2 and self-reported 
allergy to soy. These studies were registered at clinicaltrials.gov under NCT01232751 and 
NCT01556737. 
2.2 Rat experiment 
The rat experiment was performed at the Centre for Laboratory Animals (CKP, Wageningen) 
in compliance with the Dutch Act on animal experimentation (Stb, 1977, 67; Stb 1996, 565, 
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revised February 5, 1997) and was approved by the ethical committee on animal 
experimentation of Wageningen University. All procedures were considered to avoid and 
minimize animal discomfort. This experiment was a parallel study with eight-week-old female 
inbred ovariectomized (OVX) F344 rats, all equol producers, with an 8-week dosing period. 
For our analysis, data from 5 treated rats and 5 control rats were used. Further detailed 
experimental conditions are described by Islam et al. (M. A.  Islam et al., 2016).  Oral gavage 
stock of the supplement was daily and freshly prepared in 10ml water containing 1% DMSO. 
After eight weeks, the animals were anesthetized with a mixture of isoflurane and oxygen and 
blood was removed from the dorsal aorta.  
2.3 Supplements and doses 
All 3 studies were performed with the same isoflavone supplements. In the ISO study a batch 
bought in October 2010 was used, which contained 60% daidzein, 13% genistein and 27% 
glycitein. In the ISO II study and the rat experiment a batch bought in November 2011 was 
used, which had a similar isoflavone profile and contained 56% daidzein, 16% genistein and 
28% glycitein (Table 1). 
The postmenopausal women in the two studies ingested ~100 mg isoflavones/day (aglycone 
equivalents), similar to daily intakes of over-the-counter isoflavone supplements. This dose 
equivalent to 1.34 (range 0.88-1.70) and 1.42 mg/kg bw/day (range 0.94-1.81). For the animal 
study, the intake was scaled to body weight and was 2.0 mg/kg bw/day.   
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Table 1. Daily isoflavone intake in the two human intervention studies (ISO study and ISO II 
study) and the rat experiment in mg isoflavone per day and mg/kg bw calculated as aglycone 
equivalents. 
 ISO studya ISO II studya Rat 
experimentb 
 mg/day mg/ 
kg bw/day 
mg/day mg/ 
kg bw/day 
mg/ 
kg bw/day 
Total isoflavone  93.9 1.34 100.1 1.42 2.0 
Daidzin 53.2 0.76 52.0 0.74 1.0 
Daidzein 3.2 0.05 3.7 0.05 0.09 
Genistin 11.4 0.16 16.5 0.23 0.33 
Genistein 0.4 0.001 0 0 0.00 
Glycitin 23.8 0.34 26.3 0.37 0.52 
Glycitein 2.0 0.03 1.5 0.02 0.05 
a) In the human intervention studies, the absolute amount per day was the same for every 
participant; the dose per kg bw was calculated on the basis of individual bw of the participants.  
b) In the rat experiment, the dose per kg bw was similar for each rat 
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2.4 Transcriptomics 
In the human studies, gene expression after both supplement and placebo treatment was 
measured in PBMCs (n=27, all equol producers) and WAT (n=24; 7 equol producers and 17 
non-producers) by Affymetrix human gene 1.1 ST arrays (van der Velpen et al., 2013; van der 
Velpen et al., 2014). In the rat experiment, the gene expression in PBMCs and WAT (n=5 for 
the control and n=5 for the treated group, all equol producers) was measured by Affymetrix rat 
gene 1.1 ST arrays.  
2.5 Data analysis 
Data analysis of the Affymetrix chips was described before for the human studies (van der 
Velpen et al., 2013; van der Velpen et al., 2014) and the animal study (M. A.  Islam et al., 
2016). In brief, expression values of the data were calculated using the robust multichip average 
(RMA) method and normalised using quantile normalisation in MADMAX (Bolstad et al., 
2003; Irizarry et al., 2003; Lin et al., 2011). 
To compare rat and human gene expression, the rat genes were recoded into human genes using 
the Homologene database (http://www.ncbi.nlm.nih.gov/homologene) and all duplicate genes 
were removed. After this, 80.7% of the rat genes in PBMCs and 81.5% genes in WAT that 
passed filtering remained as human homologs. 
Due to the design differences in the human and the rat study, changes in gene expression in 
humans should be correctly indicated as ‘significantly changed expression of genes’, meaning 
the difference in response between start and end of the intervention. In rats, the difference in 
response between treated and control rats would be correctly named as ‘significantly different 
expressed human homologs’. However, for readability of this article, we will refer to all of 
these as ‘significantly changed genes’. 
To study whether effects on gene expression in humans were similar to rats, significantly 
changed genes in PBMCs (n=27) and WAT (n=7) from equol-producing postmenopausal 
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women were compared to the significantly changed genes in PBMCs (n=5) and WAT (n=5) of 
OVX F344 rats. Subsequently, GSEA was performed on gene expression results for the same 
four groups of PBMCs and WAT in humans and rats. The significant gene sets (false discovery 
rate (FDR) < 0.25) were visualised using Cytoscape. 
To study alleged estrogen-responsive effects of isoflavone supplementation, the significantly 
changed human genes (separate for equol producers and non-producers in human WAT) and 
significantly changed rat genes were compared to the human estrogen-responsive genes 
registered in the estrogen-responsive gene database (ERGDB, data downloaded September 
2013, (Tang et al., 2004)). 
To quantify gene expression effects in PBMCs and WAT of postmenopausal women and OVX 
rats, multivariate regression models were run with sets of log-transformed gene expression 
intensities from human and rat PBMCs and WAT as dependent variables. The human PBMC 
and WAT dataset were matched in advance to account for missing genes, which resulted in 
removal of some genes from each dataset. This process was also performed for the rat PBMC 
and WAT dataset. The multivariate analysis was performed using redundancy analysis (RDA), 
also known as least-squares reduced-rank regression (Davies & Tso, 1982; Legendre & 
Legendre, 2012). Like principal component analysis (PCA), RDA can handle any number of 
response variables (ter Braak & Šmilauer, 2012), but has the advantage over PCA that it can 
focus on the effects of explanatory variables by constraining the components (axes) by the 
explanatory variables. In our case, the explanatory variables were the isoflavone supplement 
and the two different tissues (PBMCs and WAT). All constrained components were used in 
reporting the results, and thus reduced-rank was not used because treatment effects were 
present on all axes, as judged by the relative magnitude of the eigenvalues of the constrained 
axes. The human model focused on the within-person tissue-dependent effects of isoflavone 
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supplementation compared to placebo with the following model formula (Wilkinson & Rogers, 
1973): 
[Expression of group of genes] = (supplement + supplement.tissue) | person, tissue 
where  .  denotes “interaction” and  |  means “conditional on”. 
Supplement and tissue have two levels each; supplement and placebo for supplement and 
PBMC and WAT for tissue. Person is used as a covariate to correct for the paired measurements 
(supplement and placebo) within persons. Tissue is contained in the factor person, because 
each person provided only one of the two tissues, therefore tissue is superfluous as a covariate.  
The rat model also focused on the tissue-dependent effects of the isoflavone supplement 
compared to the control: 
[Expression of group of genes] = (supplement + supplement.tissue) | tissue 
This model has the same levels for supplement and tissue as the human model and tissue as a 
covariate to correct for the PBMCs and WAT collected from the same rats.  
The models were run separately for humans and rats using Canoco 5.03 (ter Braak & Šmilauer, 
2012), both jointly and separately for PBMC and WAT samples. In the joint analysis, RDA 
estimated coefficients for each gene (dependent variable) and each explanatory variable for 
each (constrained) axis. This resulted in an explained variance (R2 in %) of the model. The 
effect sizes of the intake on gene expression were summarized by the root mean square effect 
(RMSE) on the loge-scale and shown as the summary effect size (SES in % = 100 * (e
RMSE-1)). 
The separate analysis for each tissue was used to evaluate significance of the SES using 
permutation tests producing a pseudo-F test statistic (P<0.05 and P<0.10). In the permutation 
tests, the human samples were shuffled within person, while for the rat model unrestricted 
permutations were used. In addition, intertissue correlations were derived to compare gene 
expression effects between PBMC and WAT within each of the species. Similarly, interspecies 
correlations were determined to compare gene expression effects between rats and humans for 
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each tissue separately. Correlation coefficients were calculated between the regression 
coefficients of the individual genes estimated by the separate models for PBMCs and WAT 
using SAS (SAS, version 9.3, SAS Institute, Inc., Cary, NC, USA). 
Four different sets of significantly changed genes were used as dependent variables in the 
multivariate analysis; all significantly changed genes in 1) human PBMCs, 2) human WAT, 3) 
rat PBMCs and 4) rat WAT. Another four gene sets relating to different biological pathways 
were used as well; 5) significantly changed genes from the ERGDB in both species, 6) 
oxidative phosphorylation (OXPHOS) genes present in the biological pathway of energy 
metabolism, 7) interleukin genes from inflammation pathways, 8) mitotic cell cycle genes from 
cell cycle-related pathways.   
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3 Results 
The overlap between gene expression effects in PBMCs of equol-producing postmenopausal 
women (339 genes) and PBMCs of rats (540 genes), was only 12 genes. Between gene 
expression effects in WAT of equol-producing postmenopausal women (1169 genes) and rats 
(1237 genes), the overlap was 86 genes (Figure 1 and Supplemental Table 1).  
 
 
Figure 1. Overlap between significantly changed genes in peripheral blood mononuclear cells 
(PBMCs, n=27) of postmenopausal equol-producing women and PBMCs of OVX F344 rat 
(n=10) and the overlap between these genes in white adipose tissue (WAT) of equol-producing 
women (n=7) and rat (n=10).  
 
GSEA on the gene expression data of equol producers in both species resulted in enriched gene 
sets related to energy metabolism, inflammation, cell cycle and nuclear receptor signalling, but 
not in gene sets related to estrogen signalling (Table 2). Gene sets in both tissues which were 
significantly enriched, but could not be categorized in one of the previous pathways, were 
 14 
 
specified as ‘other’. Although the gene sets in the group of ‘nuclear receptors’ are regulated in 
the same direction for both species and tissues, the other groups of gene sets have at least one 
deviating species/tissue. For example, rat PBMCs upregulated for ‘energy metabolism’, 
whereas all other groups were downregulated; human WAT upregulated for ‘inflammation’, 
but downregulated in all other groups; rat PBMCs upregulated for ‘cell cycle’, but 
downregulated in all other groups.  
 
Table 2. Results of gene set enrichment analysis on gene expression after isoflavone 
supplement intake performed for both PBMCs and WAT in postmenopausal women and OVX 
F344 rats 
  Humana Ratb 
Groups Groups of gene sets 
P
B
M
C
 
W
A
T
 
P
B
M
C
 
W
A
T
 
Energy metabolism Glucose metabolism *↓ ↓  ↓ 
 OXPHOS ↓ ↓ ↑ ↓ 
 TCA cycle *↓ ↓ ↑  
 Lipid metabolism  ↓   
 Cholesterol biosynthesis    ↓ 
 Amino acid metabolism  ↓   
Inflammation T-cell signalling  ↑  ↓ 
 B-cell signalling  ↑ ↓  
 Toll-like receptor signalling ↓ ↑  ↓ 
 Interleukin signalling  ↑ ↓ ↓ 
 Nod-like signalling ↓ ↑   
 Cytokine signalling  ↑ ↓ *↓ 
 MAPK signalling    ↓ 
 GPCR signalling ↓   *↓ 
 NFκB signalling ↓    
 Interferon signalling   ↓ ↓ 
 NGF signalling    *↓ 
 Auto immune response ↓  ↓ ↓ 
 Adaptive immunity  ↑  ↓ 
Cell cycle Mitotic cell cycle ↓ ↓ ↑  
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 Proteasome *↓ ↓ ↑ ↓ 
 Cyclin signalling  ↓ ↑ ↓ 
 mRNA metabolism   ↑  
 mRNA processing   ↑  
 Nucleosome assembly   ↑  
 tRNA amino acylation  ↓   
 Nucleotide excision repair  *↓ ↑  
 Metabolism of proteins   ↑  
 Apoptosis  ↓  ↓ 
 Protein folding  ↓ ↑  
 WNT signalling   ↑  
Nuclear receptors Nuclear receptor signalling ↓  ↓ ↓ 
 PPAR signalling ↓ ↓   
Other Synaptic transmission    ↓ 
 Complement and coagulation ↓    
 VEGF / Integrin pathway ↓ ↑  ↓ 
 Hemostasis and platelet function   *↑  
a) GSEA on human data is performed for PBMCs with n = 27 and for WAT with n = 7, all equol 
producers. 
b) GSEA on rat data is performed for n = 10 (n = 5 supplement, n = 5 placebo) for both PBMCs 
and WAT. 
↓ downregulation of effects, ↑ upregulation of effects as shown by GSEA, *effects upregulated 
or downregulated in only one or two within the group of gene sets. 
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen 
responsive; OXPHOS, oxidative phosphorylation; TCA cycle, tricarboxylic acid cycle; MAPK, 
mitogen-activated protein kinase; GPCR, G protein-coupled receptor; NFκB, nuclear factor 
kappa B; NGF, nerve growth factor; PPAR, peroxisome proliferator-activated receptors; 
VEGF, vascular endothelial growth factor. 
 
To check the ER hypothesis, 1069 estrogen-responsive genes from the ERGDB were compared 
to our data, which showed that 19 of the 339 genes (5.6%) in human PBMCs were estrogen-
responsive (Supplemental Table 2). In WAT of equol producers, 82 out of 1169 genes (7.0%) 
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were estrogen-responsive, whereas 39 out of 883 genes (4.4%) in WAT of non-producers were 
estrogen-responsive. In rats, 35 out of the 540 genes (6.5%) in PBMCs and 84 out of 1237 
genes (6.8%) in WAT were estrogen-responsive. Between the tissues and the species, only few 
genes were overlapping.  
Next to the previous qualitative evaluation of isoflavone effects, the overall gene expression 
effect was quantified. When genes with significantly changed expression in human PBMCs 
were used as dependent variables, the SES indicated 8.1% change of gene expression (P<0.05) 
in these PBMCs (Table 3). Similarly, a significant SES was obtained for human WAT (7.0%), 
which was also observed for significantly changed genes in the rat model for both PBMCs 
(23.9%) and WAT (34.0%). Smaller, non-significant, SES’ were observed, when these 
analyses were performed for the tissue from which the genes were not selected (e.g. significant 
PBMC genes vs. WAT). 
 
Table 3. Summary effect sizes (SES) of isoflavone supplementation for significantly changed 
gene expression in PBMCs and WAT, separate for the human intervention trials and the rat 
experiment  
Tissue Human intervention studiesa 
(Within-subject changes) 
 Rat experimentb  
(Between-group differences) 
 Ngenes
c PBMCd  
(%) 
WAT  
(%) 
R2model 
(%) 
Ngenes PBMC  
(%) 
WAT 
(%) 
R2model  
(%) 
PBMC 328 8.14* 4.18 11.0 536 23.9* 19.2 30.3 
WATall subjects 1158 3.16 7.01
* 6.9 1231 10.9 34.0* 35.1 
WATnon-prod
e 1158 3.15 5.02 4.9     
a) Based on two human crossover intervention trials, with 27 equol producing women for 
PBMCs, and 24 women (7 equol producers) for WAT. 
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b) Two groups (control and supplement) of 5 rats each, PBMCs and WAT collected from all 
rats. 
c) Number of significantly changed genes in tissues, rat genes decoded into human homologs. 
Number deviates from figure 1, due to matching of the datasets as described in the methods. 
d) Summary effect size (SES) in % calculated as exp((τ*sqrt(β1st axis2 + β2nd axis2)/SD)-1)*100) 
and interpreted as follows: if the exposure changes from placebo to supplement, gene 
expression for this selected group of genes changes with SES %. 
e) Analysis in 24 non-producers only for WAT 
*Significance determined by the separate models for each tissue (P<0.05). 
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue. 
 
The same analysis was performed on a selection of ER-related genes and the genes from the 
biological pathways identified using GSEA, which generated pathway-specific effect sizes of 
gene expression after isoflavone supplements (Table 4). This also resulted in larger effect sizes 
in the biological pathways of rats than of humans. For the estrogen-responsive effects, the SES 
was 5.5% (P<0.05) in WAT of postmenopausal women and 26.7% (P<0.05) for OVX rats. For 
genes related to OXPHOS, the SES were not significant. Effects on interleukin genes were 
only significant for rats with an effect size of 20.2% for PBMCs and 18.2% for WAT. Effects 
on mitotic cell cycle were only marginally significant (P<0.1) for human WAT (4.0%) and rat 
PBMCs (11.5%) and WAT (10.6%).  
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Table 4. Summary effect sizes (SES) of gene expression in PBMCs and WAT after isoflavone 
supplementation for estrogen-responsive genes and genes related to energy metabolism, 
inflammation and cell cycle 
Biological 
pathway 
Ngenes
a Human intervention studiesb 
(Within-subject changes) 
Rat experimentc 
(Between-group differences) 
  PBMCd 
(%) 
WAT 
(%) 
R2model 
(%) 
PBMC 
(%) 
WAT 
(%) 
R2model 
(%) 
ER 170 3.80* 5.52** 6.2 15.9 26.7** 24.9 
OXPHOS 58 4.02 6.73 6.3 13.5 26.1 16.0 
Interleukin 16 4.27 3.73 3.3 20.2** 18.2** 36.2 
Mitotic cell 
cycle 
30 4.35 4.00* 5.2 11.5* 10.6* 19.6 
a) Group of significantly changed genes involved in biological pathways (estrogen-responsive 
(ER), energy metabolism (OXPHOS), inflammation (Interleukin) and cell cycle (Mitotic cell 
cycle)) 
b) Based on two human crossover intervention trials, with 27 subjects for PBMCs, 24 subjects 
for WAT. 
c) Two groups of 5 rats each, all providing both PBMCs and WAT. 
d) Summary effect size (SES) in % calculated as exp((τ*sqrt(β1st axis2 + β2nd axis2)/SD)-1)*100) 
and interpreted as follows: if the exposure changes from placebo to supplement, gene 
expression for this selected group of genes changes with SES %. 
** Significance determined by the separate models for each tissue with P < 0.05 or 
* for P < 
0.10 
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen 
responsive; OXPHOS, oxidative phosphorylation. 
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Additionally, model outputs were used to calculate correlations between the regression 
coefficients of the individual genes of the two tissues and species, which resulted in significant 
interspecies correlations for ER genes in WAT (r=0.31) and for OXPHOS genes in PBMCs 
(r=0.33, Table 5). Significant intertissue correlations between PBMCs and WAT were 
observed for ER genes in humans (r=0.23) and in rats (r=0.22), and for cell cycle genes in 
humans (r=0.39) and in rats (r=0.47, Table 5). For the other biological pathways, gene 
expression effects between the tissues and the species were not significantly correlated. 
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Table 5. Intertissue and interspecies correlation coefficients for effect estimates from separate multivariate models for each tissue for estrogen-
responsive genes and genes related to energy metabolism, inflammation and cell cycle 
Biological 
pathwaya 
Intertissue correlation PBMC vs WATb Interspecies correlation human vs ratb 
Human Rat PBMC WAT 
Ngenes R (95% CI) Ngenes r (95% CI) Ngenes r (95% CI) Ngenes r (95% CI) 
ER 136 0.23 (0.06-0.38) 146 0.22 (0.05-0.36) 129 0.05 (-0.13-0.22) 166 0.31 (0.16-0.44) 
OXPHOS 57 0.05 (-0.21-0.30) 57 0.17 (-0.09-0.41) 56 0.33 (0.07-0.55) 58 0.08 (-0.18-0.33) 
Interleukin 15 -0.33 (-0.72-0.23) 15 0.29 (-0.27-0.70) 15 0.32 (-0.24-0.71) 15 0.11 (-0.43-0.59) 
Mitotic cell cycle 30 0.39 (0.03-0.67) 30 0.47 (0.13-0.71) 30 0.03 (-0.33-0.39) 30 0.14 (-0.23-0.48) 
a) Group of significantly changed genes involved in biological pathways (estrogen-responsive (ER)), energy metabolism (OXPHOS), inflammation 
(Interleukin) and cell cycle (Mitotic cell cycle))  
b) Intertissue and interspecies correlation calculated from separate models by correlating regression coefficients for the genes for both species. 
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen responsive; OXPHOS, oxidative phosphorylation. 
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4 Discussion 
In this study, effects on gene expression after isoflavone supplementation vs. placebo were 
qualitatively evaluated, further quantified and compared between PBMCs and WAT of 
postmenopausal women and OVX rats. Qualitative analysis revealed overlapping effects in 
energy metabolism, inflammation and cell cycle processes. In rats, the magnitude of gene 
expression effects after isoflavone supplementation 3 to 5-fold larger than in humans after the 
same intervention. A similar difference in magnitude (5-fold) was also observed when only ER 
genes were analysed, with significant intertissue correlations in both species (~22%) and an 
interspecies correlation in WAT (30%). Some significant effect sizes, intertissue and 
interspecies correlations were also found in biological pathways relating to OXPHOS, 
inflammation and cell cycle. 
Qualitative evaluation with GSEA revealed more similarities in effects between rats and 
humans (Table 2) than direct comparison of gene expression of individual genes (Figure 1, 
supplemental table 1), especially on gene sets related to energy metabolism, inflammation and 
cell cycle. Quantification of gene expression effects was successfully performed using a 
multivariate model, calculating summary effect sizes (SES) for expression changes in general 
(Table 3) and within biological pathways (Table 4). The observed 3-5 fold larger effect size for 
rats compared to humans (Table 3) is in line with previously observed effects on gene 
expression in genetically homogeneous inbred rat strains and in genetically independent 
women (Sparks et al., 2005). Moreover, a previous study reported an 18-fold difference in gene 
expression effects between rat and human primary hepatocytes (Black et al., 2012). In our 
study, the observed differences could be explained by the higher proportion of free isoflavones 
(aglycones) in rodents than in humans (Setchell et al., 2011) as it is hypothesized that aglycone 
forms are more bioactive than conjugated forms (M. A. Islam et al., 2015). 
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The model was applied to a set of ER genes to further evaluate the hypothesis that isoflavones 
predominantly induce their effects via the ER, which resulted in significant effect sizes in WAT 
of both species. These effects were expected as WAT is known as estrogen-responsive, while 
PBMCs are not, despite literature suggests that they display ERs (Dahlman-Wright et al., 2006; 
Wend et al., 2012). Again, for ER genes the effect size in rats (26.7%) was ~5 times greater 
than in humans (5%). In addition, it must be noted that the percentage of estrogen-responsive 
genes compared to the whole set of significantly changed genes is low (<7%) in PBMCs and 
WAT of both species (Supplemental table 2). As the early isoflavone work started with animal 
experiments (Folman & Pope, 1969; Messina, 2010), these differences in effect size could 
explain the origin of the ER hypothesis and that we were unable to confirm ER-related effects 
in human PBMCs and WAT in our two intervention studies (van der Velpen et al., 2013; van 
der Velpen et al., 2014). The additional correlation analysis in the current study suggests a 30% 
correlation between ER genes in WAT of both species. Furthermore, a ~22% correlation of the 
gene expression effects between PBMCs and WAT was found for both species. This similarity 
in both species is interesting, because of the difference in study design between the rat 
experiment and the human trials, in which the rat PBMCs and WAT samples were collected 
from the same animals, while the human PBMCs and WAT samples originated from different 
studies.  
With regard to the effect sizes and correlations of the other evaluated biological pathways, the 
results were not consistent. OXPHOS genes, used as a model for energy metabolism-related 
effects, showed no significant SES for any tissue, but did show a significant interspecies 
correlation for PBMCs. Interleukin genes, on the other hand, as a model for inflammation 
related effects, showed significant effect sizes in both rat tissues but not in human tissues, but 
no intertissue and interspecies correlations. Mitotic cell cycle genes showed borderline (<0.1) 
significant effect sizes in human WAT and rat PBMCs and WAT, and significant intertissue 
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correlations in both humans (r=0.39) and rats (r=0.47). This apparent ambiguity in outcomes 
could be explained by the selection of genes used in the analyses, but also by the roles of these 
genes in the different tissues; i.e. PBMCs play a key role in inflammation regulation of the 
body, while WAT is responsible for the regulation of energy metabolism in WAT and cell cycle 
is a general process in any tissue. The calculated correlations compare to the general 
conservation of gene expression between species, which is reported to be ~40% between human 
and mouse depending on tissue (Zheng-Bradley et al., 2010), and r~0.35 between rat and 
human (Prasad et al., 2013). In the current study, other factors could play a role in the observed 
species correlations, such as polymorphisms of the estrogen receptor (Hall et al., 2006; Y. Qin 
et al., 2014) or effects of isoflavones on DNA methylation (W. Y. Qin et al., 2009) or 
microRNAs (Xia et al., 2014). 
To our knowledge, this is the first study to compare gene expression data from human trials 
with a rat experiment in which the dose, duration and target group were aligned and the same 
methods in the same lab were used for measurement of gene expression. Despite this, effect 
sizes and correlations may be influenced by choices made in aligning the human studies and 
the rat experiment. Specifically, scaling for life expectancy was not applied, resulting in a 
similar duration for both studies (8wks). In addition, scaling for metabolic rate was not applied 
to calculate the dose, but for both species this was of a similar order of magnitude per kg bw 
(total range 0.88-1.81mg/kg bw for humans and 2mg/kg bw for rats). The difference in final 
dose could have contributed to, but cannot completely explain, the observed 3-5 fold difference 
in effect size between the two species. The presented estimates are also expected to be highly 
influenced by the selection of the groups of genes as representatives for the biological pathways 
and by removing 20% of the rat genes by recoding into human homologs. Modelling was 
complicated by the difference in study design for the human and rat experiment with regard to 
data pairing, but by choosing different covariates unbiased estimates of the effect of the 
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isoflavone supplement were obtained. In more detail, the calculated effect sizes relate to the 
baseline in each species and not to the total or residual variation, therefore the effect sizes are 
measured on the same scale, which enables comparison of effect size. In the current study, p-
values were used to select significantly changed genes for the direct comparison between 
species and tissues (Figure 1), the comparison to ER genes, as well as for the model, which 
could have resulted in an overestimation of the similarities between the species and tissues due 
to the presence of false positives. Another important issue is that rats are known to be equol 
producers (Setchell et al., 2005), while this is only the case for 20-30% of Western populations 
(Setchell & Clerici, 2010). In previous studies, differences in gene expression were observed 
between equol-producers and non-producers (Niculescu et al., 2007; van der Velpen et al., 
2014), which also applies to estrogen responsive genes (7.0% in producers, 4.4% in non-
producers). However, this difference is not always addressed in extrapolation of findings from 
isoflavone animal studies to humans. With regard to our model this means that if effects would 
be stronger and specific for equol producers, the inclusion of non-producers in the WAT data 
may have attenuated the effect estimates in humans. Indeed, the effect size was not significant 
in WAT when calculated for non-producers only (n=24, Table 3) suggesting that the reported 
effect for the whole population (n=31) might be driven by the effect in equol producers. We 
could not perform this analysis for equol producers only, because of the small number in our 
study population.  
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5 Conclusions 
In summary, our quantitative evaluation of gene expression data after isoflavone 
supplementation showed that the effect size is greater in rats than in humans. Furthermore, the 
correlations of the isoflavone supplementation effects between these species are weak, 
although they are statistically significant in a number of biological pathways, including the 
estrogen receptor pathway, known as the predominant route of biological activity of 
isoflavones. Our model provided quantitative data for the effect size in two tissues of two 
species and the correlation between these effect sizes that could be used in existing 
toxicological models, such as the parallelogram approach (Kienhuis et al., 2009a; Kienhuis et 
al., 2009c). However, to complete and verify this parallelogram approach and to draw a 
conclusion regarding possible health effects of isoflavones, data on gene expression in target 
tissue, i.e. breast and uterus, and dose-response data would be needed. While the use of gene 
expression data in risk assessment is increasing, and discussions are still ongoing regarding the 
most appropriate use of this data (Bourdon-Lacombe et al., 2015; Burgess-Herbert & Euling, 
2013), further quantitative evaluation of similarities and differences between tissues and 
species could be a step forward towards reducing uncertainty and variability in risk assessment 
practices. 
In conclusion, our model enabled quantitative comparison of gene expression data that could 
be used to further explore effect correlations between tissues and between species for risk 
assessment, in addition to the currently applied qualitative evaluation of gene expression effects 
within pathways or gene sets. 
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